Tatva Chintan Pharma Chem Limited (TATVA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Tatva Chintan Pharma Chem Limited ₹247, price ₹1,743, upside -85.8%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value ₹247.36 · Strongly overvalued (−85.8%)
!Quality 48/100
!Expensive Growth(revenue 5y +11.0 %/yr)
!Thin margins · 8.3% net margin (TTM)
!Low debt · negative free cash flow
!0.1% dividend yield · Token dividend
!Trails peers(5/13)
!Narrow moat40/100
!Evidence only low, so the estimate is less certain
Watch Tatva Chintan Pharma Chem Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹636.37 – ₹2,863 · fair‑value band ₹229.22 – ₹321.57 · the ₹1,743 price screens above the ₹247.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Tatva Chintan Pharma Chem in your weekly email
Every Wednesday you see whether Tatva Chintan Pharma Chem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally.
Show more
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Stock analysis
Tatva Chintan Pharma Chem Limited (TATVA) currently trades at ₹1,743, while our model-based Fair Value estimate is ₹247.36, 85.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹305.62 per share, and 0 of the 16 models we run sit above the ₹1,743 price.
Bear case: the Earnings-Based group reads lowest at ₹146.16, and 16 of the 16 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹229.22 (bear) to ₹321.57 (bull), the price of ₹1,743 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tatva Chintan Pharma Chem Limited reported revenue of ₹5.1B in FY2026 versus ₹4.3B in FY2022, a compound +3.9%/yr. Reported net income was ₹421M in FY2026, compounding −18.6%/yr from FY2022.
Key figures
Market cap ₹40.8B (≈ $423M) · P/E ratio 97.0 · P/S ratio 8.06 · EPS (TTM) ₹17.97 · Dividend yield 0.1% · Net margin 8.3% · Return on equity 5.5% · Return on assets (EBIT) 14.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 70% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −86%, TATVA screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹12.79 to ₹435.24). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹229.22Fair Value ₹247.36Bull ₹321.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹8.11 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.45/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
Compare Tatva Chintan Pharma Chem Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 703 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−85.8% · Bottom 25%
Profitability
Return on equity (TTM)5.5% · Below median
Return on assets3.8% · Above median
Net margin (TTM)8.3% · Above median
Operating margin (TTM)13.7% · Above median
Growth and dividend
Revenue growth24.4% · Above median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)97.0× · Priciest 25%
P/B5.22× · Priciest 25%
P/S (TTM)8.06× · Priciest 25%
EV/EBITDA43.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 50
PAST (return on equity)22· sector 25
HEALTH (low debt)100· sector 95
DIVIDEND (yield)2· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tatva Chintan Pharma Chem Limited (TATVA) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹247.36 versus a price of ₹1,743, about −86% upside (overvalued).
What is the fair value of TATVA?
Our model-based fair value for Tatva Chintan Pharma Chem Limited is ₹247.36 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹1,743.
What is the quality score of TATVA?
Tatva Chintan Pharma Chem Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tatva Chintan Pharma Chem Limited (TATVA)?
Our model-based price target is the fair value of ₹247.36 (as of Sep 27, 2026) from 16 valuation models. Cautious scenario ₹229.22, optimistic scenario ₹321.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Tatva Chintan Pharma Chem Limited stock forecast for 2026?
Our models put fair value at ₹247.36, about −86% upside versus a price of ₹1,743 (overvalued). Cautious scenario ₹229.22, optimistic scenario ₹321.57. The calculation is refreshed regularly with new filings.
What is the revenue of Tatva Chintan Pharma Chem Limited (TATVA)?
Tatva Chintan Pharma Chem Limited reported trailing-twelve-month revenue of about ₹5.1B (latest available figure, as of Sep 27, 2026).
Does Tatva Chintan Pharma Chem Limited pay a dividend?
Tatva Chintan Pharma Chem Limited currently shows a dividend yield of about 0.11% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Tatva Chintan Pharma Chem Limited (TATVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tatva Chintan Pharma Chem Limited it is ₹247.36 per share (as of Sep 27, 2026), against a price of ₹1,743. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Tatva Chintan Pharma Chem Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TATVA trades above its calculated fair value: price ₹1,743, fair value ₹247.36, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TATVA?
No. The price is what the market pays today (₹1,743); the fair value is what the company's own numbers justify (₹247.36). For Tatva Chintan Pharma Chem Limited the two are ₹1,496 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tatva Chintan Pharma Chem Limited worth?
The market values Tatva Chintan Pharma Chem Limited at about ₹40.8B (market capitalisation, as of Sep 27, 2026). Per share that is ₹1,743; our models calculate a fair value of ₹247.36 per share.
What do the bullish and bearish scenarios say about TATVA?
Our models span a range for Tatva Chintan Pharma Chem Limited: cautious scenario ₹229.22, base ₹247.36, optimistic ₹321.57 per share (as of Sep 27, 2026, price ₹1,743). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TATVA?
Tatva Chintan Pharma Chem Limited trades at a price-to-earnings ratio of 97.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹247.36 is built from several models across several years. Other multiples: P/B 5.2, P/S 8.1, EV/EBITDA 43.7.
How solid is the balance sheet of Tatva Chintan Pharma Chem Limited (TATVA)?
Balance-sheet figures for Tatva Chintan Pharma Chem Limited (as of Sep 27, 2026): return on equity 5.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is TATVA from its 52-week high?
Tatva Chintan Pharma Chem Limited trades at ₹1,743, about 3% below its 52-week high of ₹1,806 and 70% above the low of ₹1,028 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹247.36 is for.
Which stocks are comparable to Tatva Chintan Pharma Chem Limited?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tatva Chintan Pharma Chem Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹1,743, calculated fair value ₹247.36 (−86%), Quality Score 48/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TATVA calculated?
We run Tatva Chintan Pharma Chem Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹247.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tatva Chintan Pharma Chem Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tatva Chintan Pharma Chem Limited (TATVA)?
The closing price on Oct 1, 2026 was ₹1,743. Our model-based fair value is ₹247.36, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tatva Chintan Pharma Chem Limited right now?
The price sits above even our optimistic bull case (₹321.57). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Tatva Chintan Pharma Chem Limited
How large is the market capitalisation of Tatva Chintan Pharma Chem Limited (TATVA)?
The market capitalisation of Tatva Chintan Pharma Chem Limited is ₹40.8B (≈ $423M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tatva Chintan Pharma Chem Limited (TATVA)?
The price-to-sales ratio of Tatva Chintan Pharma Chem Limited is 8.06 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tatva Chintan Pharma Chem Limited (TATVA)?
Earnings per share at Tatva Chintan Pharma Chem Limited are ₹17.97 (price ÷ EPS = P/E 97.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tatva Chintan Pharma Chem Limited (TATVA)?
The dividend yield of Tatva Chintan Pharma Chem Limited is 0.1% (payout 11.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tatva Chintan Pharma Chem Limited (TATVA)?
The net margin of Tatva Chintan Pharma Chem Limited is 8.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tatva Chintan Pharma Chem Limited (TATVA)?
The return on equity (ROE) of Tatva Chintan Pharma Chem Limited is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tatva Chintan Pharma Chem Limited (TATVA)?
On an EBIT basis the return on assets of Tatva Chintan Pharma Chem Limited is 14.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tatva Chintan Pharma Chem Limited (TATVA)?
The operating margin of Tatva Chintan Pharma Chem Limited is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tatva Chintan Pharma Chem Limited (TATVA)?
Revenue at Tatva Chintan Pharma Chem Limited is growing +24.4% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tatva Chintan Pharma Chem Limited (TATVA)?
Earnings per share at Tatva Chintan Pharma Chem Limited are growing +908% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tatva Chintan Pharma Chem Limited (TATVA) generate?
The free cash flow of Tatva Chintan Pharma Chem Limited is −₹841M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tatva Chintan Pharma Chem Limited (TATVA) carry?
The net debt of Tatva Chintan Pharma Chem Limited is ₹1.1B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tatva Chintan Pharma Chem Limited in the live analysis
One click puts Tatva Chintan Pharma Chem Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
